Metronidazole Same*Gel 30G 1%,Metronidazolo Same*Gel 30G 1%,Savoma Medicinali Spa

ACTIVE substances: Metronidazole. Excipients: Ottildodecanolo, caprilocaproil macrogol-8 glycerides, carbomer, hydroxybenzoate, sodium hydroxide, sodium edetate, purified water. INDICATIONS: the drug is indicated for topical use in the treatment of papules, pustules, inflammatory and erythema rosacea. CONTRAINDICATIONS/EFF.SECONDARY: Hypersensitivity to the active substance or to any of the excipients; Contraindicated during pregnancy and lactation. DOSAGE: Apply 1-2 times a day, according to medical indications and after preliminary cleansing of the skin, to the affected areas, with a thin layer of metronidazole. Significant therapeutic results should be observed within tre weeks of starting treatment. Clinical studies have shown progressive improvement up to nine weeks of therapy. After using metronidazole, you can use cosmetics. STORAGE: Do not freeze or refrigerate. WARNINGS: While the absorption of Metronidazole is minimal when applied topically, and therefore plasma concentrations vary between yours, side effects reported as a result of oral administration of the drug have not been reported as a result of topical use. Avoid contact with eyes and mucous membranes; he reported that Metronidazole applied to the face determines lacrimazio ne. In case of contact with eyes, the gel must be removed thoroughly with water. The patient should be informed that if irritation occurs, Metronidazole should be used less frequently or therapy should be temporarily suspended. Avoid exposure to ultraviolet light (sun, UV lamps, tanning bed equipment) while you are taken with metronidazole. Since the drug is a nitroimidazole derivative it should be used with caution in patients presenting with pathological blood changes or with medical history data associated with them. The product should be used as directed by your healthcare professional. Do not exceed recommended doses. Use, especially long-term, according to scientists for external use, can lead to sensitization phenomena. There are no adequate clinical data on the effectiveness and safety of metronidazole in children, therefore metronidazole should not be used in children. Do not swallow. INTERACTIONS: Due to the low blood levels resulting from topical use of Metronidazole, interactions with other drugs are unlikely. However, you should remember that disulfiram-like reactions have been reported in a small number of patients who were taking metronidazole and alcohol at the same time, and in the case of treating patients who were undergoing concomitant anticoagulant therapy, it should be taken into account that Metronidazole, after administration of oral , determines the potentiation of the effects of anticoagulants, d elle coumarin and warfarin, which manifests itself by causing a long prothrombin time. The effect of topical metronidazole on prothrombin time is not known. ADVERSE EFFECTS: The following side effects have been reported following the use of topical metronidazole. Diseases of the skin and tissue under the skin: contact dermatitis, dry skin, erythema, itching, rash, skin irritation (burning and pricking sensation), skin irritation, transient redness and exacerbation of rosacea. Eye diseases: lacrimation. None of these side effects occurred in more than 2% of patients. PREGNANCY AND LACTATION: The safety of metronidazole during pregnancy has not been sufficiently proven. Conflicting reports are available, especially in the first stage of pregnancy. Some studies have shown and made recommendations for increasing the strain rate. R risk of possible complications, including carcinogenic risk, this was not yet clear. Metronidazole is contraindicated during the first trimester of pregnancy. During the central quarter and during the ult im trimester of pregnancy, metronidazole should be prescribed with ol in case of ineffectiveness of other treatment methods. Following oral administration, metronidazole is excreted into breast milk in concentrations similar to those found in plasma. Following topical administration, the drug reaches plasma levels significantly lower than those obtained after oral administration, so the importance of treatment for the mother is to be considered when stopping breastfeeding or treatment with medication.